image: Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine, is a pioneer in generative AI for drug discovery. view more
Credit: Insilico Medicine
Alex Zhavoronkov, PhD, an expert in generative artificial intelligence (AI) for drug discovery and founder and CEO of Insilico Medicine (“Insilico”), will present at NextMed Health at the Hotel Del Coronado in San Diego on March 14 at 5pm PT. NextMed Health brings together a diverse group of healthcare professionals, entrepreneurs, academics, investors, patients, and public health experts to tackle significant challenges in healthcare. Zhavoronkov will present on the panel “Accelerating Cures and the Future of Pharma.”
Insilico is a leading innovator in advancing new therapeutics using generative AI and reinforcement learning and has developed an end-to-end Pharma.AI platform for identifying novel targets (PandaOmics), designing new drugs (Chemistry42), and predicting the outcomes of clinical trials (InClinico). The platform has produced two drugs that have reached clinical trials. Insilico’s lead drug for the devastating chronic lung disease idiopathic pulmonary fibrosis (IPF), the first AI-discovered and AI-designed drug to advance to clinical trials, will soon be entering Phase 2 trials with patients. And Insilico recently announced that its generative AI-designed drug for COVID-19 and related variants has been approved for clinical trials and has a number of design advantages over existing COVID-19 drugs.
There are 30 drugs in Insilico’s internal pipeline available for partnering and licensing for indications including cancer, fibrosis and immunology, and the Company has also partnered with top pharma companies like Fosun and Sanofi to advance their programs.
Focused on healthcare innovation, NextMed Health unites thought leaders and disruptors from different fields, breaking down barriers in healthcare innovation across the technology, care, and biomedical continuum. The event features a combination of physical and virtual gatherings and thought-provoking content and curation.
Founded in 2014, Insilico Medicine has raised over $400m in funding to date from notable biotech and tech investors and has won numerous awards, including, in 2022, the BioCentury-BayHelix Company of the Year award and Top 100 AI Companies by CB Insights.
About Insilico Medicine
Insilico Medicine, a clinical stage generative artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases and aging-related diseases. Headquartered in Hong Kong, Insilico Medicine has additional offices in New York, Montreal, Shanghai, Suzhou, Taipei, and Abu Dhabi. www.insilico.com